MedCity News August 26, 2024
The industry is increasingly under attack by lawmakers from both parties for drug prices most Americans regard as unreasonable, so the election outcome could be pivotal to drug companies’ fortunes.
Former President Donald Trump and Vice President Kamala Harris have a rare point of agreement in their otherwise bitter and divisive contest: It’s up to the government to cut high U.S. drug prices.
Harris cast the tie-breaking Senate vote in 2022 for legislation that allows Medicare to negotiate drug prices for its more than 60 million beneficiaries. Before that, she was an aggressive regulator of the drug industry as California attorney general.
As president, Trump would likely retain Medicare price negotiations unless the pharmaceutical industry can come up with something...
Today's Sponsors
Today's Sponsor